Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Hormone Receptor-Positive Breast Carcinoma|Recurrent Breast Carcinoma
Interventions: DRUG: Abemaciclib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Copanlisib Hydrochloride|PROCEDURE: Diagnostic Imaging|PROCEDURE: Echocardiography|DRUG: Fulvestrant|PROCEDURE: Multigated Acquisition Scan
Sponsor: National Cancer Institute (NCI)